Calcium Acetate Versus Calcium Carbonate as Oral Phosphate Binder: Preparation and In Vitro Assessment Calcium acetate as oral phosphate binder
Iranian Journal of Pharmaceutical Sciences,
Vol. 1 No. 2 (2005),
1 April 2005
,
Page 107-114
https://doi.org/10.22037/ijps.v1.39453
Abstract
Calcium acetate is used as an oral phosphate binder to control hyperphosphatemia in patients with chronic renal failure. Compared to calcium carbonate,
control of hyperphosphatemia can be achieved at lower calcium administration with calcium acetate which likely reduces the risk of hypercalcemia. In this study,
various formulations of calcium acetate tablets were prepared and their disintegration times, dissolution rates and phosphate binding capacities were determined. Dissolution test was carried out using the paddle method according to the United States Pharmacopoeia (USP XXIII). The binding efficiency of the tablets was compared by measuring the amount of insoluble phosphate after mixing with a sodium phosphate solution at pH 6. Calcium acetate tablets had a mean content of 809.6 mg of calcium acetate and a mean weight of 1087 mg. The average breaking load and disintegration times were 66.4±5.5 N and 24.5±2.1 min, respectively. Drug release after 30 and 60 min were 80.45% and 101.42%, respectively. The amount of nondissolved phosphorus following 60 min incubation of calcium acetate and/or calcium carbonate tablets were 372.8 mg (61.2%) and 463.2 mg (76.0%), respectively.
Weight variation, friability, disintegration time, and dissolution rate of calcium
acetate tablets were in the acceptable pharmacopoeial limits. Ahigh phosphate binding
capacity of calcium acetate tablets indicated that it can be a suitable alternative to
calcium carbonate in the management of hyperphosphatemia in patients with
chronic renal failure.
- Calcium acetate
- Phosphate binders
- Dissolution
How to Cite
References
[2] Delmez JA, Slatapolsky E. Hyperphosphatemia: its consequences and treatment in patients with chronic renal disease. Am J Kidney Dis 1992; 19: 303-17.
[3] Ekman M, Reizenstein P, Teigen SW, Ronneberg R. Comparative absorption of calcium from carbonate tablets, lactogluconate/carbonate effervescent tablet, and chloride solution. Bone 1991; 12: 93-7.
[4] Hansen C, Werner E, Erbes HJ, Larrat V, Kaltwasser JP. Intestinal calcium absorption from different calcium preparations: influence of anion and solubility. Osteoporos Int 1996; 6: 386-93.
[5] Whiting SJ, Pluhator MM. Comparison of in vitro and in vivo tests for determination of availability of calcium from calcium carbonate tablets. J Am Coll Nutr 1992; 11: 553-60.
[6] Biagini M, Malaguti M, Sicoli R, Capece R, Friggi A, Ciaffi G, Bargagna R. Treatment of uraemic hyperphosphatemia with calcium acetate: a safe alternative to calcium carbonate. Biomater Artif Cells Immobilization Biotechnol 1992; 20: 1193-9.
[7] Moriniere P, Djerad M, Boudailliez B, Espern B, Biotte F, Westell PF, Compagnon M, Brazier M, Achard JM, Foumier A. Control of predialytic hyperphosphatemia by oral calcium acetate and calcium carbonate. Nephron 1992; 60: 6-11.
[8] d’Almeida Filho EJ, da Cruz EA, Hoette M, Ruzany F, Keen LN, Lugon JR. Calcium acetate versus calcium carbonate in the control of hyperphosphatemia in hemodialysis patients. Sao Paulo Med J 2000; 118: 179-84.
[9] Janssen MJ, van der Kuy A, Wee PM, van Boven WP. Aluminum hydroxide, calcium carbonate and calcium acetate in chronic intermittent hemodialysis patients. Clin Nephrol 1996; 45: 111-9.
[10] Carr CJ, Shangraw RF. Nutritional and pharmaceutical aspects of calcium supplementation. Am Pharm 1987; NS27: 149-57.
[11] Mason NA, Patel JD, Dressman JB, Shimp LA. Consumer vinegar test for determining calcium disintegration. Am J Hosp Pharm 1992; 49: 2218-22.
[12] British Pharmacopoeia 28. London: The Pharmaceutical Press, 1993; pp. 98-9, A144.
[13] Wells JI. Pharmaceutical preformulation. Chichester, West Sussex: Ellis Horwood Limitted, 1988; pp. 209-15.
[14] Aulton EM. Pharmaceutics, the science of dosage form design. Hong Kong: Longman Group, 1988; pp. 248-9, 306-7, 313, 603-4.
[15] US Pharmacopoeia (USP XXIII) /national formulary 18. Rockville: the United States Pharmacopeial Convention, 1995; pp. 247, 1791, 1838, 1981.
[16] Kobrin SM, Goldstein SJ, Shangraw RF, Raja RM. Variable efficacy of calcium carbonate tablets. Am J Kidney Dis 1989; 14: 461-5.
[17] Brennan MJ, Duncan WE, Wartofsky L, Butler VM, Wray HL. in vitro dissolution of calcium carbonate preparations. Calcif Tissue Int 1991; 49: 308-12.
[18] Gohel MC, Panchal MK. Novel use of similarity factors f2 and SD for the development of diltiazem HCl modified-release tablets using a 3(2) factorial design. Drug Dev Ind Pharm 2002; 28: 77-87.
[19] Sheikh MS, Maguire JA, Emmett M, Santa Ana CA, Nicar MJ, Schiller LR, Fordtran JS. Reduction of dietary phosphorus absorption by phosphorus binders: a theoretical, in vitro, and in vivo study. J Clin Invest 1989; 83: 66-73.
[20] Emmett M, Sirmon MD, Kirkpatrick WG, Nolan CR, Schmitt GW, Cleveland MB. Calcium acetate control of serum phosphorus in hemodialysis patients. Am J Kidney Dis 1991; 17: 544-50.
[21] Sousa MF, Abumrad NN, Martins C, Nissen S, Riella MC. Calcium beta-hydroxy-betamethylbutyrate: 1. potential role as a phosphate binder in uremia, in vitro study. Nephron 1996; 72: 391-4.
[22] Tavakoli N, Shahidi SH, Baghbani N. Formulation, physicochemical and clinical evaluation of calcium carbonate tablets. Pharm. D. thesis, Faculty of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, 1999; pp. 55-6.
[23] Dal Zotto M, Ragazzi E, Realdon N, Dalla Fini G. Technological testing of calcium carbonate tablets for use in the treatment of renal osteodystrophy. IL Farmaco 1993; 48: 989-1005.
[24] Remington’s Pharmaceutical Sciences. 19th ed., Pensylvania: Mack Publishing Company, 1995; pp.1641-2.
[25] Heaney RP, Rocker RR, Weaver CM. Absorbability of calcium sources, the limited role of solubility. Calcif Tissue Int 1990; 46: 300-4.
[26] Cabana BE, O’Neill R. FDA’s report on drug dissolution. Pharmacopeial Forum 1980; 6: 71-5.
- Abstract Viewed: 323 times
- IJPS_Volume 1_Issue 2_Pages 107-114 Downloaded: 301 times